AIKIDO PHARMA INC (AIKI)

Company Profile

AIkido Pharma, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The Company’s pipeline consists of patented technology from universities and researchers. The firm advances its therapeutic drug pipeline through a collaboration with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The company is also developing a broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. Its pancreatic drug candidate, DHA-dFdC, developed at and licensed from the University of Texas at Austin, is a chemotherapy treatment for advanced pancreatic cancer.

Company Info

AIKIDO PHARMA INC

One Rockefeller Plaza, 11Th Floor

New York City NEW YORK 10020

P: 13473217646.0

CEO: Anthony Hayes

Employees: 4

Website: https://aikidopharma.com/